As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
HOME > REGULATORY
REGULATORY
- LDP Lawmakers Not So Positive about Reflecting Societal Values to Drug Prices; They Don’t Know How
March 22, 2019
- MHLW Orders Label Revisions for Takecab, Clozapine and More
March 20, 2019
- Japan Cabinet OKs Bill to Amend PMD Law
March 20, 2019
- Generic Drug Use Rates Particularly Low for Insurance Societies of Research-Driven Drug Makers: MHLW
March 20, 2019
- MHLW Council Rejects OTC Switches of 4 Alzheimer’s Drugs
March 19, 2019
- MHLW Council Recommends OTC Switch of Polycarbophil Calcium
March 19, 2019
- PMD Bill Clears LDP Review, Cabinet OK Slated for March 19
March 18, 2019
- MHLW Council to Draft Negotiation Rules on Supply of Unapproved Drugs under Patient-Initiated Mix Care Scheme
March 18, 2019
- Japan Cabinet OKs PMDA Review Fee Rise from April 1
March 18, 2019
- MHLW Seeks Opposition Party Understanding on Removal of Officer Change Order Provision from Amendment Bill for PMD Law
March 15, 2019
- MHLW Grants Orphan Status to Cx601, Takeda’s 1st Cell Therapy
March 15, 2019
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- HSC Committee Continues to Discuss Reorganizing Core Clinical Research Hospitals
March 15, 2019
- Xofluza-Resistant Viruses Detected in Xofluza-Naïve Patients: NIID
March 15, 2019
- MHLW’s Panel Compiles Interim Paper for Promotion of Clinical Research, Trials
March 14, 2019
- Dismissal Order Provision Erased from PMD Law Amendment Bill
March 14, 2019
- MHLW Calls for Cooperation in Genomic Research on Drug-Induced Muscle Disorders
March 14, 2019
- MHLW to Promote Master Protocol Trials to Boost Efficiency in New Drug Development
March 14, 2019
- MHLW Likely to Tweak PMD Law Amendment Bill as Lawmaker Frowns on Order to Change Pharmaceutical Affairs Officer
March 13, 2019
- MHLW Panel Approves Shift from “Relative Contraindications” to “Contraindications” for 5 Drugs/Drug Groups
March 13, 2019
ページ
While grappling with sluggish revenues in Japan last year amid 1.7% negative market growth as put by IQVIA, mega pharma companies saw their upbeat oncology franchises increasingly buttress their businesses in the country, helping them soften the blows from generic…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…